**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 88774

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma**

Wang YY *et al.* Role of MTDH in HCC

Yi-Ying Wang, Mei-Mei Shen, Jian Gao

**Yi-Ying Wang, Mei-Mei Shen,** Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

**Jian Gao,** Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

**Author contributions:** Wang YY and Shen MM performed the experiments and wrote the manuscript; Gao J revised the manuscript; all the authors have approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 82173359; Basic Research and Frontier Exploration Project of Chongqing and Technology Commission, No. cstc2018jcyjAX0181; and Kuanren Talents Program of The Second Affiliated Hospital of Chongqing Medical University.

**Corresponding author: Jian Gao, PhD, Doctor,** Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Chongqing Medical University, No. 76 Linjiang Road, Yuzhong District, Chongqing 400010, China. 982213482@qq.com

**Received:** October 8, 2023

**Revised:** December 18, 2023

**Accepted:** January 24, 2024

**Published online:** February 28, 2024

**Abstract**

BACKGROUND

Metadherin (*MTDH*) is a key oncogene in most cancer types, including hepatocellular carcinoma (HCC). Notably, *MTDH* does not affect the stemness phenotype or immune infiltration of HCC.

AIM

To explore the role of *MTDH* on stemness and immune infiltration in HCC**.**

METHODS

*MTDH* expression in HCC tissues was detected using TCGA and GEO databases. Immunohistochemistry was used to analyze the tissue samples. *MTDH* was stably knocked down or overexpressed by lentiviral transfection in the two HCC cell lines. The invasion and migration abilities of HCC cells were evaluated using Matrigel invasion and wound healing assays. Next, we obtained liver cancer stem cells from the spheroids by culturing them in a serum-free medium. Gene expression was determined by western blotting and quantitative reverse transcription PCR. Flow cytometry, immunofluorescence, and tumor sphere formation assays were used to characterize stem-like cells. The effects of *MTDH* inhibition on tumor growth were evaluated *in vivo*. The correlation of *MTDH* with immune cells, immunomodulators, and chemokines was analyzed using ssGSEA and TISIDB databases.

RESULTS

HCC tissues expressed higher levels of *MTDH* than normal liver tissues. High *MTDH* expression was associated with a poor prognosis. HCC cells overexpressing *MTDH* exhibited stronger invasion and migration abilities, exhibited a stem cell-like phenotype, and formed spheres; however, *MTDH* inhibition attenuated these effects. *MTDH* inhibition suppressed HCC progression and CD133 expression *in vivo*. *MTDH* was positively correlated with immature dendritic, T helper 2 cells, central memory CD8+ T, memory B, activated dendritic, natural killer (NK) T, NK, activated CD4+ T, and central memory CD4+ T cells. *MTDH* was negatively correlated with activated CD8+ T cells, eosinophils, activated B cells, monocytes, macrophages, and mast cells. A positive correlation was observed between the *MTDH* level and *CXCL2* expression, whereas a negative correlation was observed between the *MTDH* level and *CX3CL1* and *CXCL12* expression.

CONCLUSION

High levels of MTDH expression in patients with HCC are associated with poor prognosis, promoting tumor stemness, immune infiltration, and HCC progression.

**Key Words:** Metadherin; Hepatocellular carcinoma; Cancer stem cells; Immune infiltration

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Wang YY, Shen MM, Gao J. Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma. *World J Gastroenterol* 2024; 30(8): 901-918

**URL**: https://www.wjgnet.com/1007-9327/full/v30/i8/901.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v30.i8.901

**Core Tip:** This study demonstrated that high metadherin (*MTDH*) expression is associated with poor prognosis in hepatocellular carcinoma (HCC). High *MTDH* expression increased the invasion and migration abilities of HCC cells and promoted stemness and self-renewal. Moreover, *MTDH* influenced immune cell infiltration and chemokine levels. These results provide additional evidence for the potential role of *MTDH* as a molecular marker for HCC.

**INTRODUCTION**

Primary liver cancer is one of the six most common cancers and the third leading cause of cancer-related deaths worldwide. About 75%-85% of primary liver cancer cases are caused by hepatocellular carcinoma (HCC)[1]. The treatment of liver tumors, is limited by its complex pathogenesis, postoperative recurrence, and drug resistance[2]. The poor prognosis of patients with this disease is attributable to metastasis and high recurrence rates. Therefore, it is crucial to understand the relevant mechanisms underlying HCC and identify new therapeutic approaches and targets.

According to several studies, a small proportion of tumor cells, including those in HCC and colorectal cancer, are capable of self-renewal, proliferation, and differentiation, and they are referred to as cancer stem cells (CSCs)[3,4]. The surface markers of CSCs in HCC include CD133, CD90, and EpCAM. High expression levels of CSC markers of CSCs increase stem cell characteristics and tumor sphere-forming capacity[5-7]. An infiltration of multiple immune cells occurs in HCC, including T lymphocytes[8], B cells[9], dendritic cells (DCs)[10] , and natural killer (NK) cells[11]. The HCC consists of these tumor-infiltrating immune cells. The type and number of immune cells have prognostic value and can influence the response to immunotherapy.

Metadherin (*MTDH*), also known as astrocyte elevated gene-1 or lysine-rich *CEACAM1*, is a key oncogenic gene in most cancer types[12]. In malignant tumors, *MTDH* promotes proliferation capacity[13], migration[14], cell survival, and angiogenesis[15], as well as poor prognosis, in lung, prostate, and breast cancers. The importance of *MTDH* in HCC has been demonstrated in numerous studies[16,17]; however, the effects of the expression of *MTDH* on stem cell characteristics and immune cell infiltration in HCC remain unclear.

Compared with normal liver tissues, liver cancer tissues showed higher levels of *MTDH* expression. Notably, *MTDH* expression was associated with poor prognosis. Our findings showed that *MTDH* was expressed at higher levels in tumor spheres than in adherent cells. *MTDH* expression in HCC cells positively correlated with *CD133*, *Oct4*, and *Nanog* expression in stem cells. Furthermore, the inhibition of *MTDH* expression inhibited tumor growth. Our study confirmed that *MTDH* is associated with immune cell infiltration, as confirmed by the analysis of the ssGSEA and TISIDB databases.

**MATERIALS AND METHODS**

***HCC Samples***

All the gene expression profile files and the clinical information were obtained from two public databases. TCGA (The Cancer Genome Atlas database, https://portal.gdc.cancer.gov/) contains information on transcriptional gene expression in human cancer and healthy tissues. After removing samples with incomplete clinical information, 369 liver tumor tissues and 50 healthy liver tissues were analyzed. In the GEO (Gene Expression Omnibus, www.ncbi.nlm.nih.gov/geo/), incompletely annotated samples were excluded from the dataset of GSE14520 (sequencing platform: GPL3921). The analysis included 210 samples, comprising both tumor samples and their corresponding non-cancer pairs. The clinical information of all the samples is presented in Table 1. Liver tumor tissue microarrays of nine paired samples (HLivH030PG03) were purchased from Shanghai Xinchao (Shanghai, China).

***Differential expression and survival analyses***

TCGA data were converted to TPM (transcripts per million) values for subsequent analyses. For GSE14520, data normalization and log2 transformation were performed. Probe IDs were converted to gene symbols using a platform annotation file. Genes with multiple probes are represented by their maximum expression values. Data pre-processing was performed, followed by differential expression and statistical analyses using R software. A survival curve analysis was performed using the R packages "Survival" and "Survminer" with the best cut-off value for *MTDH* calculated for both datasets. R packages “ggstatsplot” and “corrplot” were used for data visualization.

***Cell culture***

Huh7 cells were purchased from the Chinese Academy of Sciences Cell Bank and, MHCC-97H cells were obtained from the Liver Cancer Institute at Fudan University Zhongshan Hospital. All the cells were cultured in DMEM medium [10% fetal bovine serum (FBS)], 100 U/mL penicillin, and 100 U/mL streptomycin in an incubator with 5% CO2.

***Sphere formation assay***

Tumor spheres were cultured in serum-free medium (SFM) consisting of 20 ng/mL EGF (PeproTech), DMEM/F12 (HyClone), 20 ng/mL bFGF (PeproTech), and 20 μL/mL B27 (Gibco). Single cells (1 × 104) were seeded in a 6-well ultra-low adsorption plate (Corning) containing 1.5 mL of serum-free culture medium. All the cells were incubated for 14 d in incubators with 5% CO2 at 37°C. Inverted microscopes were used to count tumor spheres larger than 50 mm.

***Extraction of proteins and western blotting***

To prepare proteins from the cells, the cells were lysed in RIPA solution (CWBIO) containing a protease inhibitor cocktail solution. The protein concentration in the solution was determined using a BCA kit (Beyotime). Proteins were separated by using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (Beyotime Millipore) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). PVDF membranes were closed with 5% skim milk at room temperature (RT) for 1 h, followed by overnight incubation with primary antibody at 4°C. The membranes were washed thrice with TBST containing 0.1% Tween-20, followed by incubation with secondary antibodies (EarthOx) (1:5000) for 1 h. After washing thrice with TBST, for 5 min, the blots were visualized with chemiluminescence reagents (Beyotime). The antibodies used were anti-MTDH (CST, 14065T), anti-CD133 (YT5192, ImmunoWay), anti-NANOG (CST, 4903T), and anti-GAPDH (YM3215, ImmunoWay).

***Total RNA extraction and real-time quantitative reverse transcription PCR***

TRIzol (Takara) was used to extract RNA from the cells, and the cDNA (complementary DNA) composition was determined using the PrimeScriptTM RT Reagent Kit (TaKaRa). Real-time quantitative reverse transcription PCR (qRT-PCR) was performed using SYBR Premix Ex Taq (TaKaRa Bio). A CFX96 Real-Time PCR Detection System (Bio-Rad) was used for qRT-PCR analysis. PCR was performed using the primers purchased from Sangon Biotechnology (Shanghai, China). The 2-ΔΔCt method was used to calculate the data. Table 2 shows primer sequences.

***Cell transfection***

To establish a cell line with stable overexpression and suppression of *MTDH*, the cell were infected with a lentivirus. MTDH-overexpressing lentiviral vectors, MTDH-RNAi lentiviral vectors, and blank control lentiviral vectors were acquired from GeneChem (Shanghai, China). On the previous day, 3 × 104 cells were grown in each well of a six-well plate. When the cells reached 30% confluence, they were transfected according to the manufacturer’s protocols at Multiplicity of Infection of 5. After 96 h, fluorescence microscopy and western blotting were used to verify the transfection efficiency. Puromycin screening was then performed for 2 wk (GeneChem).

***Immunofluorescence***

The cells were seeded in a 24-well plate. Paraformaldehyde solution (4%) was used to fix the cells for 20 min after 24 h of incubation. For cell membrane permeabilization, the cells were treated with 0.3% TritonX-100 (Sigmautes) for 15 min. The cells were incubated overnight with anti-NANOG antibody at 4°C after 120 min incubation in 5% BSA in TBST. Next, the cells were washed thrice with PBS and incubated with DyLight 649 AffiniPure Goat Anti-Rat IgG (1:200, Abbkine) for 1 h in a dark humidified box. The final counterstaining was done using DAPI (4',6-diamino-2-phenylindole) for 10 min. Images were captured using a fluoresce microscope (Nikon).

***Wound healing assay***

MHCC-97H and Huh7 cells were cultured in six-well plates. Subsequent experiments were performed when the cell density in the wells reached 90%. After scratching the cells with a 200-mL pipette, 2% FBS cell culture medium was used for continued culture. All the cells were incubated with 5% carbondioxide in an incubator at 37°C. A microscope was used to photograph the wounded areas.

***Invasion and migration assays***

The migration and invasion abilities of the cells were assessed using 24-well transwell chambers with or without Matrigel (BD Biosciences). The supplements were kept in 5% CO2 at 37°C for 12 h. Next, 2 × 105 cells were re-suspended in 200 μL of SFM and placed in transwell cups with an 8-micron pore membrane (BD). Simultaneously, cell culture medium containing 10% FBS was added to the lower layer to make a total volume of 600 μL. The chambers were maintained in 5% CO2 for 24 h at 37°C. The cells that failed to pass through the pores and remained in the upper chamber were carefully wiped off with a cotton swab. Migrating cells were fixed in 4% paraformaldehyde solution for 20 min. Next, the cells remaining in the chambers were stained in 200 μL 0.1% crystal violet for 30 min, followed by counting with a microscope in five random areas.

***Flow cytometry***

The cells were washed with PBS after trypsin digestion. Next, they were suspended in 80 μL of PBS, followed by the addition of 2 μL PE-CD133 antibody (Miltenyi Biotec) and 20 μL of FcR Blocking Reagent (Miltenyi Biotec). Under light-proof conditions, the mixture was incubated at 4°C for 10 min. Next, all the cells were washed thrice in PBS, followed by resuspension with 500 μL of PBS. The mixture was analyzed using a FACS Calibur Flow cytometer (BD Biosciences).

***Animal experiments***

BALB/c-nu mice were obtained from the Animal Experiment Center of Chongqing Medical University. The experiments were conducted in the animal facilities of the Animal Experiment Center of Chongqing Medical University (12-h light/dark cycle, 27 ± 2°C, 50% ± 10% humidity). Nude mice were randomly divided into two groups of three mice each. MHCC-MTDH-LV cells (2 × 106 cells) were re-suspended in a complete culture medium. Next, 100 μL of cell suspension were subcutaneously injected into nude mouse (female, 4–6 wk old). The tumors were detached after 4 wk. Next, the tumor volume was calculated using the following formula: Length × width2/2. Tumor tissues were subjected to immunohistochemical staining (IHC) analysis. This study was approved by the Ethics Committee of the Second Hospital of Chongqing Medical University.

***IHC***

All the slides were dewaxed and gradually hydrated. Antigen extraction was performed using citrate buffer under high pressure and temperature conditions. All the slides were rinsed with PBS and incubated with goat serum for 10 min at RT. Next, the slides were exposed to anti-MTDH and anti-CD133 at 4°C overnight. Subsequently, horseradish peroxidase-labeled streptavidin was added, followed by the addition of DAB reagent. Tap water was dehydrated using an ethanol gradient. The slides were then washed twice with xylene and wrapped in neutral balsam. Protein expression levels were assessed using the ImageJ software. The average optical density was calculated by measuring the integrated optical density and the area of each image, which reflected the concentration per unit area of the target protein.

***ssGSEA***

The infiltration abundances of 28 immune cell species in TCGA samples were quantified using ssGSEA. The gene set data for the immune cells were downloaded from the website (https://www.cell.com/cms/10.1016/j.celrep.2016.12.019/). Box plots were constructed to compare immune cell differences between the groups. The R package used was “GSVA”[18], “ggplot2.”

***TISIDB database***

TISIDB is an online analysis site for the analysis of tumor-immune interactions (http://cis.hku.hk/TISIDB/)[19]. To further investigate the immunological impact of MTDH in cancer, we analyzed and evaluated the TISIDB database through the "Immunomodulators" and “chemokine modules”.

***Statistical analysis***

All the experiments were conducted at least thrice. Data were analyzed using R 4.1.2 and GraphPad Prism software. Student's t-test was used to compare two groups of continuous variables. The Kruskal-Wallis and Wilcox tests were used for non-parametric tests. A *P* value < 0.05 indicated statistical significance.

**RESULTS**

***MTDH is upregulated in HCC and positively associated with poor prognosis***

To identify aberrant *MTDH* expression in HCC, we downloaded microarray gene profiling data from GEO (GSE14520/GPL3921) and TCGA. In 50 normal liver tissues and 369 Liver cancer tissues from TCGA, *MTDH* mRNA expression was upregulated in liver tumor tissues. Similarly, *MTDH* expression was increased in the tumor in GSE14520 (*n* = 420; Figure 1A and B). *MTDH* expression was examined in human HCC (*n* = 9) and paracancerous tissues (*n* = 9) using IHC. According to these results, HCC tissues overexpressed *MTDH*, compared with the para-cancerous tissues (Figure 1C). Furthermore, we constructed the Kaplan-Meier curve of HCC using “Survival” and “Survminer” R packages. Shorter survival times were associated with higher MTDH (Figure 1D and E). A higher expression of *MTDH* was observed in liver cancer tissues than in normal liver tissues or para-cancerous tissues, which had impact on the prognosis of patients with liver cancer.

***MTDH promotes HCC cell migration and invasion***

Two cell lines, Huh7 and MHCC-97H, were transfected with the related lentiviruses. Specifically, we used a blank control (LV-NC) *vs* overexpression (LV-OE) and a blank control (LV-NC) *vs* knockdown (LV-RNAi), to obtain stable overexpression and suppression of *MTDH*. Western blotting was performed to verify MTDH protein expression after transfection (Figure 2A). The migration and invasion assays showed that *MTDH* overexpression significantly accelerated the migration and invasion of MHCC-97H and Huh7 cells (Figure 2B). Conversely, *MTDH* knockdown cells exhibited lower potential for migration and invasion (Figure 2C). The wound healing assay confirmed that *MTDH* overexpression significantly promoted wound healing, whereas *MTDH* knockdown suppressed scratch wound healing in HCC cells (Figure 2D). These results indicate that high *MTDH* expression correlates positively with the migration and invasive abilities of HCC cells.

***MTDH is associated with the CSCs phenotypes in HCC***

To determine whether *MTDH* is related to the stem cell phenotype, we examined *MTDH* and HCC stemness using TCGA database. TCGA data showed a significant positive correlation between *MTDH* expression in HCC tissues and *CD133*, *NANOG*, and *Oct4* expression (*n* = 369; Figure 3A). Our previous research confirmed that liver CSCs (LCSCs) can be enriched using a serum-free stem cell medium to promote tumor sphere formation. Next, we performed SFM on MHCC-97H and Huh7 cells, followed by western blotting and qRT-PCR to determine MTDH expression in stem cell spheres and attached cells. Compared with liver cancer-adherent cells, LCSCs expressed increased mRNA levels of MTDH and the stem cell markers (*CD133*, *Oct4*, and *Nanog*; Figure 3B). The results showed that the protein expression levels of MTDH, CD133, and NANOG were higher than those in liver cancer adherent cells (Figure 3C). These results showed that MTDH was highly expressed in LCSCs.

***Overexpression of MTDH******enhances the LCSCs phenotypes***

TTo confirm that MTDH maintained stem-like phenotypes in HCC cells, stem cell markers were detected in MHCC-97H and Huh7 cell lines overexpressing MTDH (*CD133*, *Oct4*, *Nanog*). Through PCR experiments, we demonstrated that the markers of CSCs markers were higher in MTDH-overexpressing cells than in the NC groups (Figure 4A). MTDH-overexpressing Huh7 and MHCC-97H cells also expressed high levels of CD133 and Nanog protein (Figure 4B). A The sphere culture assay showed the formation of more spheres in MTDH-overexpressing Huh7 and MHCC-97H cells than in control cells (Figure 4C). Flow cytometry revealed that MTDH overexpression effectively increased the number of CD133+ HCC cells (Figure 4D). In addition, MTDH overexpression effectively enhanced CSCs phenotypes in HCC cells.

***MTDH knockdown inhibits LCSCs phenotypes***

The PCR results demonstrated that the mRNA expression of stem cell markers in MTDH-RNAi cells was lower than that in the NC group (Figure 5A). In contrast to the NC group, MTDH-RNAi cells showed lower expression of *CD133* and *Nanog* (Figure 5B). The downregulation of MTDH reduced the numbers of both MHCC-97H and Huh7 cell spheres, compared with those in the control LV-NC group, as indicated by the results of the sphere culture assay (Figure 5C). The results of the immunofluorescence showed that Nanog fluorescence intensity was greater in the NC group than in the MTDH-RNAi group (Figure 5D). Taken together, these results confirm that the inhibition of *MTDH* expression attenuates the acquisition of the HCC stem cell phenotype.

***MTDH knockdown reduces tumor growth and CD133 expression in vivo***

Male BALB/c nude mice were injected with LV-NC or LV-MTDH-RNAi MHCC-97H cells to evaluate the effect of *MTDH* on tumor growth. The MTDH-RNAi group exhibited a smaller tumor volume than the 97H-NC group, confirming that *MTDH* promotes tumor growth (Figure 6A and B). Images of hematoxylin and eosin-stained tumor tissues of nude mice are shown in Figure 6C. To further clarify the role of *MTDH* in the tumor stem cell phenotype, CD133 and MTDH proteins were detected by IHC in the tumor tissues of nude mice. We found that CD133 expression decreased with reduced MTDH expression (Figure 6D). Therefore, these results further suggest that *MTDH* overexpression promotes liver tumor growth and the CSCs phenotype.

***MTDH expression and immune cell infiltration***

A significant association was observed between immune cell infiltration and survival in patients with HCC. Using ssGSEA, we quantified immune cell infiltration scores in HCC samples from TCGA to understand the relationship between *MTDH* and infiltration. Firstly, the results demonstrated a significantly higher infiltration of activated B cell, immature B, memory B, activated CD8 T, gamma delta T, effector memory CD8 T, central memory CD8 T, and effector memory CD4 T cells in healthy tissue than in HCC. Similarly, higher infiltration of eosinophils, immature DCs, myeloid-derived suppressor cells, monocytes, macrophages, mast cells, monocytes, neutrophils, NK cells, NK T cells, and T helper (Th) cells were observed in healthy tissue than in HCC (Figure 7A). These findings suggest that immune cells are essential in the progression of HCC. Based on the median *MTDH* expression, we divided the liver cancer samples in TCGA into high and low *MTDH* expression groups and assessed immune cell infiltration in both groups. Notably, the levels of memory B (*P* < 0.0001), immature dendritic (*P* < 0.001), Th2 (*P* < 0.001), and central memory CD4+ T (*P* < 0.01) cells were higher in the high *MTDH* expression group than that in the low group. In the low *MTDH* expression group, activated CD8 T cells (*P* < 0.0001), macrophages (*P* < 0.01), activated B cells (*P* < 0.01), effector memory CD8 T cells (*P* < 0.01), mast cells (*P* < 0.01), eosinophils (*P* < 0.05), monocytes (*P* < 0.05), and Th1 cells (*P* < 0.05) were significantly increased (Figure 7B).

We examined the relationship between immune cells and *MTDH* expression (Figure 8A). Immature dendritic (*r* = 0.28, *P* < 0.0001; Figure 8B), Th2 (*r* = 0.26, *P* < 0.0001; Figure 8C), memory B (*r* = 0.25, *P* < 0.0001; Figure 8D), central memory CD4 T (*r* = 0.22, *P* < 0.0001; Figure 8E), central memory CD8 T, NK T, activated dendritic, activated CD4 T, and NK cells also showed a positive relationship with *MTDH*. Activated CD8 T cells (*r* = -0.23, *P* < 0.0001; Figure 8F), eosinophils (*r* = -0.13, *P* < 0.05; Figure 8G), activated B cells (*r* =-0.12, *P* < 0.05; Figure 8H), monocytes (*r* = -0.12, *P* < 0.05; Figure 8I), macrophages, and mast cells showed a negative correlation with *MTDH*.

***Correlation of MTDH expression with immunomodulators and chemokines***

ICIs (immune checkpoint inhibitors) are gaining increasing attention as tumor immunotherapy strategies for different types of cancers, facilitating improved prognosis in some patients. *MTDH* and the various immunosuppressive agents in the TISIDB database did not show significant correlation, as indicated by our online analysis (Figure 9A). However, in the analysis of correlation with immunostimulants (Figure 9B), a positive correlation was found between *MTDH* and *MICB* (*r* = 0.207, *P* = 5.76 × 10-5; Figure 9C), *NT5E* (*r* = 0.201, *P* = 9.8 × 10-5; Figure 9D), and *TNFSF14* (*r* = 0.143, *P* = 0.00576; Figure 9E). Based on these results, *MTDH* may be involved in the regulation of tumor immunity.

Chemokines and their receptors induce cell migration. The expression of *MTDH* correlated with that of chemokines and receptors in immune cells, based on the data from the TISIDB database (Figure 10A and B). In HCC, *MTDH* expression positively correlated with *CXCL2* (*r* = 0.224, *P* = 1.34 × 10-5; Figure 10C) and negatively correlated with *CX3CL1* (*r* = 0.245, *P* = 1.73 × 10-6; Figure 10D) and *CXCL12* (*r* = 0.208, *P* = 5.4 × 10-5; Figure 10E). However, *MTDH* expression was not significantly correlated with chemokine receptor expression.

**DISCUSSION**

This study demonstrated that *MTDH* expression was higher in HCC tissues than in normal liver tissues and was associated with shorter survival time, stronger migration, and invasive ability. This study also focused on the effects of *MTDH* on stemness acquisition and immune infiltration of HCC cells. *MTDH* promotes stemness in HCC cells and high *MTDH* expression may impede the effectiveness of cancer immunotherapy. The findings of this study will provide additional information that can enhance the understanding of the prognosis and treatment of HCC patients.

It has been reported that the expression level of *MTDH* correlates with serum alpha-fetoprotein level[20], microvascular infiltration, tumor differentiation, and TNM stage[21]. In addition, the 1-year, 3-year and 5-year overall survival (OS) rates of the high-expression group were significantly lower than those of the low-expression group, and the cumulative recurrence rate was significantly higher than that of the low-expression group[21]. Univariate and multivariate analyses identified AEG-1 as an independent prognostic factor for OS and recurrence[22]. The findings of Yoo *et al*[22] showed that *MTDH* expression gradually increased in phases I-IV and from high differentiation to low differentiation. Differential expression, immunohistochemistry, and survival analysis showed similar results. The findings indicate that *MTDH* is closely associated with poor clinical prognosis of HCC. Additional studies have revealed that *MTDH* participates in proliferation, tumor progression, invasiveness[23], and metastasis[13]. We performed invasion, migration, and scratch assays on HCC cell lines with overexpressed and under-expressed *MTDH*. The results suggest that *MTDH* plays a role in HCC progression, which is consistent with the report of Yoo *et al*[22].

CSCs are capable of promoting metastasis and enhancing resistance to tumor therapies, including liver cancer therapy[24]. *CD133*, *NANOG*, *Oct4*, and several other molecular markers related to stemness maintenance in human CSCs have been reported[25,26]. Notably, *CD133* is a surface marker for LCSCs. The co-expression of *Nanog* and *OCT4* is associated with aggressive tumor behavior and worse clinical outcomes in HCC cells. A study by Hu *et al*[27] found strong correlations among *MTDH*, *CD133,* and *SOX2* Levels in gliomas. However, the contribution of *MTDH* to the tumor stem cell phenotype in HCC remains unclear. We explored the correlation between *MTDH* and stem cell markers in HCC using correlation analysis and experimental studies. The three stemness markers in the TCGA LIHC dataset exhibited positive correlation with *MTDH* expression. Additionally, MTDH expression increased in HCC spheres. The overexpression of *MTDH* in HCC cells enhanced their self-renewal ability, increased the proportion of CD133+ cells, and promoted the expression of tumor stemness markers. However, after *MTDH* knockdown, stem cell markers were less expressed, and self-renewal was suppressed. The tumorigenic experiments were performed using nude mice. The primary tumor size was reduced in the *MTDH*-suppressed group, with decreased CD133 protein expression. These results confirm that *MTDH* plays a regulatory role in HCC stem cells Therefore, in this study, we demonstrated that *MTDH* promoted an increase in tumor stem cells in HCC cells, which could lead to a worse prognosis.

*MTDH* can influence the Wnt/β-catenin, Ha-ras, and PI3K/Akt pathways. The Wnt/β-catenin pathway maintains the CSCs phenotype[28]. In gastric cancer, *MTDH* forms a complex with *β-Catenin* and *LEF1*, facilitating the promotion of β-catenin protein translocation and activation of genes downstream of Wnt signaling[29]. CD133 glioma cells overexpressing *MTDH* maintain stemness and drug resistance through Wnt/β-catenin protein signaling[27]. The precise mechanism through which *MTDH* regulates CSCs in HCC should be further elucidated in the future.

*MTDH* increases the expression of PD-L1 and up-regulates the transcriptional activity of PD-L1 through the β-catenin/lev-1 signaling pathway. Patients with HCC and high *MTDH* and PD-L1 expression may benefit more from PD-1 monoclonal therapy. This suggests that *MTDH* is associated with immunity against HCC[30]. Immunotherapy resistance in tumor cells is related to components outside the tumor cells in the tumor microenvironment. Mature DCs can induce specific immune responses in the body, acting as anti-infection and anti-tumor agents. Conversely, immature DCs can inhibit the function of antigen-specific effector T cells in the body to further induce immune tolerance. There are different subpopulations of CD4+ Th cells, which include Th1, Th2, and Th17 cells. It has been shown that Th2 cytokines (IL-4 and IL-10) promote tumor growth and metastasis, while Th1 cytokines (IL-2 and TNF-α) are associated with a good prognosis in HCC[31,32]. We found that a high level of *MTDH* expression positively correlated with an increase in Th2 cells and immature DCs. We speculated that *MTDH* may increase immune tolerance and metastasis of tumor cells by regulating the infiltration level of immature DC or Th2 cells, which in turn leads to poor prognosis in patients. In contrast, *MTDH* exhibited negative correlation with the infiltration levels of activated CD8+ T cells, eosinophils, activated B cells, and monocytes. These findings suggest that *MTDH* plays a critical role in regulating tumor immune infiltration in HCC.

*MTDH* significantly correlated with the immunostimulants (*MICB*, *NT5E*, and *TNFSF14*). Chemokines initiate lymphocyte infiltration early in the development of malignancies to enhance the activities of antitumor agents. Chemokines reduce apoptosis, promote proliferation, enrich CSCs in tumors, and increase the resistance of tumor cells to therapy[33]. Analyzing the TISIB database revealed a positive correlation between *MTDH* and *CXCL2* expression levels and a negative correlation between *MTDH*, *CXCL12*, and *CX3CL1* expression levels. *CXCL2* promotes the invasion and migration of HCC cells[34]. The recurrence rate of intrahepatic or extrahepatic metastases is lower in patients with HCC expressing high levels of *CX3CL1* and its receptor, *CX3CR1*[35]. HPMEC (human lung microvascular endothelial cells) exhibit an MTDH-mediated attraction towards suspension-cultured cells through the CXCR4/CXCL12 axis, suggesting that MTDH promotes HCC cell metastasis through the CXCR4/CXCL12 pathway[36]. Our analysis showed that MTDH expression negatively correlated with *CCXCL12* and *CXCR4,* but not significantly with *CXCR4*. This finding was inconsistent with our anticipated results. Exploring the interactions and the associated mechanisms between *CCXCL12* and *MTDH* will further elucidate the role of *MTDH* in HCC.

This study had some limitations. The exact mechanism through which *MTDH* influences HCC stem cells needs further investigation both *in vivo* and *in vitro*. Additionally, although we found that *MTDH* expression was closely associated with immune infiltration and prognosis, a more in-depth investigation is essential to elucidate the exact mechanism of MTDH-mediated immune infiltration.

**CONCLUSION**

High *MTDH* expression is associated with poor prognosis in HCC. *MTDH* may influence HCC progression through the regulation of tumor stemness and immune infiltration, providing additional evidence for the possible role of *MTDH* as a potential molecular marker of HCC.

**ARTICLE HIGHLIGHTS**

***Research background***

Metadherin (*MTDH*) is a key oncogene in most cancer types, including hepatocellular carcinoma (HCC). Tumor stem cells are associated with tumorigenesis, metastasis, cell proliferation, and postoperative recurrence. The type and number of immune cells in the HCC microenvironment have prognostic value and can influence the response to immunotherapy. The impacts of *MTDH* expression on stem cell characteristics and immune cell infiltration in HCC remain unclear.

***Research motivation***

*MTDH* is a key oncogene in most cancers. It is important to explore the impact of *MTDH* on the prognosis of HCC patients and determine whether it affects tumor progression by influencing stem cell phenotype and immune infiltration.

***Research objectives***

This study aimed to investigate the effects of *MTDH* on tumor stemness and immunity in HCC.

***Research methods***

Differential expression of *MTDH* in tissues was detected using TCGA and GEO databases, and immunohistochemistry was performed on HCC and para-cancerous tissue samples. *MTDH* was stably downregulated or overexpressed by lentiviral transfection in both HCC cell types. Invasiveness and migration were assessed using stromal infiltration and wound healing assays. HCC stem cells were obtained by culturing spheroids in a serum-free medium. Flow cytometry, immunofluorescence, and sphere formation assays were used to identify stem-like cells. Relevant gene expression was detected through western blotting and real-time quantitative reverse transcription-PCR. The effect of *MTDH* inhibition on tumor growth was investigated using *in vivo* tumor formation assays. Correlations between *MTDH* and immune cells, immunomodulators, and chemokines were analyzed using ssGSEA and the TISIDB database.

***Research results***

This study confirmed that the expression of *MTDH* in HCC tissues was higher than that in normal liver tissues and that the high expression of *MTDH* resulted in poor prognosis of patients with HCC. HCC cells overexpressing *MTDH* exhibited stronger invasion and migration abilities, exhibited a stem cell-like phenotype, and formed spheres, whereas *MTDH* inhibition attenuated these effects. *MTDH* inhibition suppressed tumor growth and CD133 expression *in vivo.* Correlation analysis showed that *MTDH* exhibited positive correlation with immature dendritic cells (DCs), T helper (Th)2 cells, central memory CD8+ T cells, memory B cells, activated DCs, natural killer (NK) T cells, NK cells, activated CD4+ T cells, and central memory CD4+ T cells. The results also showed that *MTDH* exhibited negative correlation with activated CD8+ T cells, eosinophils, activated B cells, monocytes, macrophages, and mast cells. Correlation analysis of *MTDH* expression with immunomodulators and chemokines showed that *MTDH* levels positively correlated with *CXCL2* expression and negatively correlated with *CX3CL1* and *CXCL12* expression.

***Research conclusions***

In HCC, *MTDH* expression is increased, leading to poor prognosis. *MTDH* promotes the acquisition of tumor cell stemness and tumor growth in HCC, influencing immune infiltration and immunotherapy.

***Research perspectives***

Through database analysis, as well as *in vivo* and *in vitro* experiments, we confirmed that *MTDH* leads to poor prognosis in patients with HCC, promotes the acquisition of the tumor stem cell phenotype, and influences immune infiltration. The exact mechanism through which *MTDH* influences HCC stem cell and immune cell infiltration requires further exploration. This may provide a scientific basis for further understanding of the prognosis and treatment of patients with HCC.

**ACKNOWLEDGEMENTS**

We would like to thank Institute of Life Sciences, Chongqing Medical University for technical support.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 **Kim M**, Lee SJ, Shin S, Park KS, Park SY, Lee CH. Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells. *Sci Rep* 2018; **8**: 10668 [PMID: 30006566 DOI: 10.1038/s41598-018-29048-8]

3 **Wang T**, Wu H, Liu S, Lei Z, Qin Z, Wen L, Liu K, Wang X, Guo Y, Liu Q, Liu L, Wang J, Lin L, Mao C, Zhu X, Xiao H, Bian X, Chen D, Xu C, Wang B. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance. *Cancer Lett* 2018; **430**: 11-24 [PMID: 29746925 DOI: 10.1016/j.canlet.2018.05.003]

4 **Rhee H**, Chung T, Yoo JE, Nahm JH, Woo HY, Choi GH, Han DH, Park YN. Gross type of hepatocellular carcinoma reflects the tumor hypoxia, fibrosis, and stemness-related marker expression. *Hepatol Int* 2020; **14**: 239-248 [PMID: 31993941 DOI: 10.1007/s12072-020-10012-6]

5 **Cao J**, Zhao M, Liu J, Zhang X, Pei Y, Wang J, Yang X, Shen B, Zhang J. RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog. *Theranostics* 2019; **9**: 811-828 [PMID: 30809310 DOI: 10.7150/thno.29271]

6 **Liu F**, Kong X, Lv L, Gao J. TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. *Cancer Lett* 2015; **359**: 288-298 [PMID: 25633840 DOI: 10.1016/j.canlet.2015.01.030]

7 **Xu N**, Li X, Watanabe M, Ueki H, Hu H, Li N, Araki M, Wada K, Xu A, Liu C, Nasu Y, Huang P. Induction of cells with prostate cancer stem-like properties from mouse induced pluripotent stem cells *via* conditioned medium. *Am J Cancer Res* 2018; **8**: 1624-1632 [PMID: 30210930]

8 **Barsch M**, Salié H, Schlaak AE, Zhang Z, Hess M, Mayer LS, Tauber C, Otto-Mora P, Ohtani T, Nilsson T, Wischer L, Winkler F, Manne S, Rech A, Schmitt-Graeff A, Bronsert P, Hofmann M, Neumann-Haefelin C, Boettler T, Fichtner-Feigl S, van Boemmel F, Berg T, Rimassa L, Di Tommaso L, Saeed A, D'Alessio A, Pinato DJ, Bettinger D, Binder H, John Wherry E, Schultheiss M, Thimme R, Bengsch B. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. *J Hepatol* 2022; **77**: 397-409 [PMID: 35367533 DOI: 10.1016/j.jhep.2022.02.032]

9 **Garnelo M**, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. *Gut* 2017; **66**: 342-351 [PMID: 26669617 DOI: 10.1136/gutjnl-2015-310814]

10 **Suthen S**, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, Wan WK, Pang YH, Soon G, Cheow PC, Kam JH, Iyer S, Kow A, Tam WL, Shuen TWH, Toh HC, Dan YY, Bonney GK, Chan CY, Chung A, Goh BKP, Zhai W, Ginhoux F, Chow PKH, Albani S, Chew V. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. *Hepatology* 2022; **76**: 1329-1344 [PMID: 35184329 DOI: 10.1002/hep.32419]

11 **Ducimetière L**, Lucchiari G, Litscher G, Nater M, Heeb L, Nuñez NG, Wyss L, Burri D, Vermeer M, Gschwend J, Moor AE, Becher B, van den Broek M, Tugues S. Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis. *Proc Natl Acad Sci U S A* 2021; **118** [PMID: 34183415 DOI: 10.1073/pnas.2026271118]

12 **Sarkar D**, Fisher PB. AEG-1/MTDH/LYRIC: clinical significance. *Adv Cancer Res* 2013; **120**: 39-74 [PMID: 23889987 DOI: 10.1016/B978-0-12-401676-7.00002-4]

13 **Chen J**, Jia Y, Jia ZH, Zhu Y, Jin YM. Silencing the expression of MTDH increases the radiation sensitivity of SKOV3 ovarian cancer cells and reduces their proliferation and metastasis. *Int J Oncol* 2018; **53**: 2180-2190 [PMID: 30226587 DOI: 10.3892/ijo.2018.4541]

14 **Zhu K**, Dai Z, Pan Q, Wang Z, Yang GH, Yu L, Ding ZB, Shi GM, Ke AW, Yang XR, Tao ZH, Zhao YM, Qin Y, Zeng HY, Tang ZY, Fan J, Zhou J. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. *Clin Cancer Res* 2011; **17**: 7294-7302 [PMID: 21976539 DOI: 10.1158/1078-0432.CCR-11-1327]

15 **Emdad L**, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, Fisher PB. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. *Proc Natl Acad Sci U S A* 2009; **106**: 21300-21305 [PMID: 19940250 DOI: 10.1073/pnas.0910936106]

16 **Zhang W**, Zhangyuan G, Wang F, Jin K, Shen H, Zhang L, Yuan X, Wang J, Zhang H, Yu W, Huang R, Xu X, Yin Y, Zhong G, Lin A, Sun B. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. *Immunity* 2021; **54**: 1168-1185.e8 [PMID: 34038747 DOI: 10.1016/j.immuni.2021.04.027]

17 **Jin C**, Han-Hua D, Qiu-Meng L, Deng N, Peng-Chen D, Jie M, Lei X, Xue-Wu Z, Hui-Fang L, Yan C, Xiao-Ping C, Bi-Xiang Z. MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma. *Oncogene* 2023; **42**: 169-183 [PMID: 36385375 DOI: 10.1038/s41388-022-02545-x]

18 **Hänzelmann S**, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013; **14**: 7 [PMID: 23323831 DOI: 10.1186/1471-2105-14-7]

19 **Yu G**, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 2012; **16**: 284-287 [PMID: 22455463 DOI: 10.1089/omi.2011.0118]

20 **Al-sheikh NM,** El-Hefnway SM, Abuamer AM, Dala AG. Metadherin mRNA expression in hepatocellular carcinoma. *Egypt J Medical Hum Genet* 2018; **19**: 391-397 [DOI: 10.1016/j.ejmhg.2018.02.002]

21 **Jung HI**, Ahn T, Bae SH, Chung JC, Kim H, Chin S, Jeong D, Cho HD, Lee MS, Kim HC, Kim CH, Baek MJ. Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor. *Ann Surg Treat Res* 2015; **88**: 77-85 [PMID: 25692118 DOI: 10.4174/astr.2015.88.2.77]

22 **Yoo BK**, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, Mills AS, Waxman S, Fisher RA, Llovet JM, Fisher PB, Sarkar D. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. *J Clin Invest* 2009; **119**: 465-477 [PMID: 19221438 DOI: 10.1172/JCI36460]

23 **Tokunaga E**, Nakashima Y, Yamashita N, Hisamatsu Y, Okada S, Akiyoshi S, Aishima S, Kitao H, Morita M, Maehara Y. Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. *Breast Cancer* 2014; **21**: 341-349 [PMID: 22903204 DOI: 10.1007/s12282-012-0398-2]

24 **Chen P**, Hsu WH, Han J, Xia Y, DePinho RA. Cancer Stemness Meets Immunity: From Mechanism to Therapy. *Cell Rep* 2021; **34**: 108597 [PMID: 33406434 DOI: 10.1016/j.celrep.2020.108597]

25 **Vlashi E**, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. *Semin Cancer Biol* 2015; **31**: 28-35 [PMID: 25025713 DOI: 10.1016/j.semcancer.2014.07.001]

26 **Liu F**, Kong X, Lv L, Gao J. MiR-155 targets TP53INP1 to regulate liver cancer stem cell acquisition and self-renewal. *FEBS Lett* 2015; **589**: 500-506 [PMID: 25601564 DOI: 10.1016/j.febslet.2015.01.009]

27 **Hu B**, Emdad L, Kegelman TP, Shen XN, Das SK, Sarkar D, Fisher PB. Astrocyte Elevated Gene-1 Regulates β-Catenin Signaling to Maintain Glioma Stem-like Stemness and Self-Renewal. *Mol Cancer Res* 2017; **15**: 225-233 [PMID: 27903708 DOI: 10.1158/1541-7786.MCR-16-0239]

28 **Mao J**, Fan S, Ma W, Fan P, Wang B, Zhang J, Wang H, Tang B, Zhang Q, Yu X, Wang L, Song B, Li L. Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. *Cell Death Dis* 2014; **5**: e1039 [PMID: 24481453 DOI: 10.1038/cddis.2013.515]

29 **Pandit H**, Li Y, Li X, Zhang W, Li S, Martin RCG. Enrichment of cancer stem cells *via* β-catenin contributing to the tumorigenesis of hepatocellular carcinoma. *BMC Cancer* 2018; **18**: 783 [PMID: 30075764 DOI: 10.1186/s12885-018-4683-0]

30 **Wan JL**, Wang B, Wu ML, Li J, Gong RM, Song LN, Zhang HS, Zhu GQ, Chen SP, Cai JL, Xing XX, Wang YD, Yang Y, Cai CZ, Huang R, Liu H, Dai Z. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy. *Cancer Lett* 2022; **541**: 215750 [PMID: 35609735 DOI: 10.1016/j.canlet.2022.215750]

31 **Zhou L**, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. *Immunity* 2009; **30**: 646-655 [PMID: 19464987 DOI: 10.1016/j.immuni.2009.05.001]

32 **Mantovani A**, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008; **454**: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]

33 **Morein D**, Erlichman N, Ben-Baruch A. Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy. *Front Immunol* 2020; **11**: 952 [PMID: 32582148 DOI: 10.3389/fimmu.2020.00952]

34 **Lu Y**, Li S, Ma L, Li Y, Zhang X, Peng Q, Mo C, Huang L, Qin X, Liu Y. Type conversion of secretomes in a 3D TAM2 and HCC cell co-culture system and functional importance of CXCL2 in HCC. *Sci Rep* 2016; **6**: 24558 [PMID: 27117207 DOI: 10.1038/srep24558]

35 **Matsubara T**, Ono T, Yamanoi A, Tachibana M, Nagasue N. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. *J Surg Oncol* 2007; **95**: 241-249 [PMID: 17323338 DOI: 10.1002/jso.20642]

36 **Zhou Z**, Deng H, Yan W, Luo M, Tu W, Xia Y, He J, Han P, Fu Y, Tian D. AEG-1 promotes anoikis resistance and orientation chemotaxis in hepatocellular carcinoma cells. *PLoS One* 2014; **9**: e100372 [PMID: 24941119 DOI: 10.1371/journal.pone.0100372]

**Footnotes**

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by The Ethics Committee of the Second Hospital of Chongqing Medical University [Protocol No. 2023(4)].

**Conflict-of-interest statement:** No conflict of interest has been declared by any of the authors.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 8, 2023

**First decision:** December 6, 2023

**Article in press:** January 24, 2024

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Reshkin SJ, Italy **S-Editor:** Lin C **L-Editor:** A **P-Editor:** Chen YX


**Figure Legends**




**Figure 1 Metadherin overexpression has been linked to a worse prognosis in hepatocellular carcinoma.** A and B: Metadherin (*MTDH*) mRNA expression in normal liver tissues compared with liver cancer tissues; C: Images of para-carcinoma (*n* = 9) and cancer tissues (*n* = 9) stained with *MTDH* by Immunohistochemical staining (scale bar = 200 μm); D and E: Patient's overall survival curves according to *MTDH* expression. a*P* < 0.0001, b*P* < 0.01. Normal: Normal liver tissues; Cancer: Liver cancer tissues; Para-carcinoma: Para-cancerous tissue; MTDH: Metadherin; IHC: Immunohistochemical staining.




**Figure 2 Metadherin promotes proliferation, migration, and invasion of hepatocellular carcinoma cells.** A: In Huh7 and MHCC-97H cells, Western blotting revealed the efficacy of Metadherin overexpression and knockdown; B and C: Characteristic images of trans-well invasion assays 24 h after culture; D: Images depicting scratch width at 0 h and 48 h post-scratch in cells captured using inverted microscopy. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001, d*P* < 0.0001. OE: Metadherin overexpression group; NC: Overexpression control group; RNAi: Metadherin knockdown group; RNAi-NC: MTDH knockdown control group.




**Figure 3 Metadherin correlates with the stemness properties in hepatocellular carcinoma.** A: Correlation between Metadherin (*MTDH*) and *CD133*, *Nanog*, *Oct4* in TCGA; B: Through quantitative reverse transcription PCR, the expression levels of *MTDH*, *CD133*, *Nanog*, *Oct4* were measured in attached cells and tumor spheres in 97H and Huh7 cell lines. In tumor spheres, all the four genes were expressed at increased levels; C: MTDH, CD133, and Nanog were higher in attached cells than in tumor spheres. Gene GAPDH served as the internal reference. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001, d*P* < 0.0001.CSC: Cancer stem cells; CC: Cancer cells.




**Figure 4 Metadherin overexpression promotes stem cell phenotypes and self- renewal in hepatocellular carcinoma cell lines.** A and B: Through quantitative reverse transcription PCR polymerase chain reaction and Western blot, we determined Metadherin expression and stemness markers; C: The typical pictures of sphere formation assays from 97H-overexpression and Huh7-overexpression cells; D: Flow cytometric analysis of CD133+ cells in 97H-overexpressing and Huh7-overexpressing cells. a*P* < 0.05, b*P* < 0.01. OE: Metadherin overexpression group; NC: Overexpression control group; MTDH: Metadherin.




**Figure 5 Metadherin downregulation inhibits hepatocellular carcinoma stem cell phenotypes.** A: mRNA expression of Metadherin (*MTDH*), *CD133*, *Nanog*, and *Oct4* in 97H and Huh7-RNAi; B: In comparison with that of MTDH-LV-RNAi, the protein expression of CD133 and Nanog was elevated in MHCC-97H-NC and Huh7-NC cells; C: Images depicting sphere formation by 97H-RNAi and Huh7-RNAi cells; D: Immunofluorescence images of *Nanog* (red) in 97H-LV and Huh7-LV samples. DAPI (blue) was used to stain the nuclei. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. RNAi: Metadherin knockdown group; RNAi-NC: Metadherin knockdown control group.




**Figure 6 Metadherin stimulates tumorigenesis *in vivo.*** A:Tumors derived from nude mice injected with 97H-RNAi (*n* = 3), 97H-NC cell (*n* = 3); B: Tumor volume showed that the inhibition of Metadherin (*MTDH*) significantly inhibited tumor growth; C and D: Representative immunohistochemical staining (IHC) images of tumors from nude mice stained with CD133 and MTDH. Histograms show the IHC score. Histograms show the IHC score (scale bars = 200 μm). a*P* < 0.01, b*P* < 0.001, c*P* < 0.0001. RNAi: Metadherin knockdown group; RNAi-NC: Metadherin knockdown control group.




**Figure 7 Infiltration of immune cells in TCGA samples using ssGSEA.** A: Immune cell infiltration between LIHC samples and normal samples; B: Different immune cell infiltration patterns in high and low expression samples of Metadherin. a*P* < 0.05; b*P* < 0.01; c*P* < 0.001, d*P* < 0.0001.



**Figure 8 Immune infiltration and Metadherin expression levels.** A: Metadherin (*MTDH*) expression levels correlated with infiltration of immune cells; B: Correlations between *MTDH* and immature dendritic cells (*r* = 0.28, *P* < 0.0001); C: Correlations between *MTDH* and T helper 2 cells (*r* = 0.26, *P* < 0.0001); D: Correlations between *MTDH* and memory B cells (*r* = 0.25, *P* < 0.0001); E: Correlations between *MTDH* and central memory CD4 T cells (*r* = 0.22, *P* < 0.0001); F: Correlations between *MTDH* and activated CD8 T cell (*r* = -0.23, *P* < 0.0001); G: Correlations between *MTDH* and eosinophils (*r* = -0.13, *P* < 0.05); H: Correlations between *MTDH* and activated B cells (*r* =-0.12, *P* < 0.05); I: Correlations between *MTDH* and monocytes (*r* = -0.12, *P* < 0.05). MTDH: Metadherin.



**Figure 9 Correlation between Metadherin expression and immunomodulators.** A and B: Heat map showing the correlation between Metadherin (*MTDH*) and immunosuppressive agents and immunostimulants in hepatocellular carcinoma; C: Correlations between *MTDH* and *MICB*; D: Correlations between *MTDH* and *NT5E*; E: Correlations between *MTDH* and *TNFSF14*. MTDH: Metadherin.



**Figure 10 Chemokines and chemokine receptor correlates with Metadherin.** A and B:A correlation analysis of Metadherin (*MTDH*) and chemokines and the receptors in LIHC is presented as a heat map; C: Correlations between *MTDH* and *CXCL2*; D: Correlations between *MTDH* and *CX3CL1*; E: Correlations between *MTDH* and *CXCL12*. MTDH: Metadherin.

**Table 1 Description of the datasets used in this study**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Clinical characteristics** | [**GSE14520**](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520) | | **TCGA** | |
| Total (*n* = 210) | % | Total (*n* = 369) | % |
| **Age** |  |  |  |  |
| < 60 | 169 | 80.48 | 168 | 45.53 |
| ≥ 60 | 41 | 19.52 | 200 | 54.20 |
| Unknown | – | – | 1 | 0.27 |
| **Gender** |  |  |  |  |
| Female | 26 | 12.38 | 120 | 32.52 |
| Male | 184 | 87.62 | 249 | 67.48 |
| **T stage** |  |  |  |  |
| T1 | – | – | 179 | 48.51 |
| T2 | – | – | 94 | 25.47 |
| T3 | – | – | 80 | 21.68 |
| T4 | – | – | 13 | 3.52 |
| Unknown | – |  | 3 | 0.81 |
| **N stage** |  |  |  |  |
| N0 | – | – | 250 | 67.75 |
| N1 | – | – | 4 | 1.08 |
| Nx | – |  | 114 | 30.89 |
| Unknown | – | – | 1 | 0.27 |
| **M stage** |  |  |  |  |
| M0 | – | – | 264 | 71.55 |
| M1 | – | – | 4 | 1.08 |
| Mx | – | – | 101 | 27.37 |
| **Stage** |  |  |  |  |
| I | 90 | 42.86 | 169 | 45.80 |
| II | 75 | 35.71 | 86 | 23.31 |
| III | 43 | 20.48 | 85 | 23.04 |
| IV | 0 | 0.00 | 5 | 1.36 |
| Unknown | 2 | 0.95 | 24 | 6.50 |
| **Status** |  |  |  |  |
| Alive | 130 | 61.90 | 241 | 65.31 |
| Dead | 80 | 38.10 | 128 | 34.69 |
| Unknown | – | – | 0 | 0.00 |
| **HBV status** |  |  |  |  |
| AVR-CC | 52 | 24.76 | – | – |
| CC | 152 | 72.38 | – | – |
| Unknown | 6 | 2.86 | – | – |

HBV: H**epatitis B** virus; AVR: Active viral replication chronic carrier; CC: Chronic carrier.

**Table 2** **Primers used in this study**

|  |  |  |
| --- | --- | --- |
| Gene | Forward | Reverse |
| Metadherin | 5′-CCAGGCTCCTTCATCAACTT-3′ | 5′-AthAAGCAGCCACCAGAGATTG-3′ |
| CD133 | 5′-TGGATGCAGACCTTGACAACGT-3′ | 5′-ATACCTGCTACGACAGTCGTGGT-3′ |
| Nanog | 5′-AATACCTCAGCCTCCAGCAGATG-3′ | 5′- TGCGTCACACCATTGCTATTCTTC -3′ |
| Oct4 | 5′-CAGGAGGCATTGCTGATGAT-3′ | 5′-GAAGGCTGGGGCTCATTT-3′ |
| GAPDH | 5′-CAGGAGGCATTGCTGATGAT-3′ | 5′- GAAGGCTGGGGCTCATTT -3′ |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**